Compositions and dosage forms for oral delivery
AssigneeRhodes Technologies
InventorsPing Chang, Marc Brown, Charles Evans
Life of this patent
Estimating the term…
Abstract
The present disclosure provides pharmaceutical compositions comprising a cannabinoid, and dosage forms comprising same, for oral delivery, such as sublingual or buccal delivery. The compositions of the present disclosure are substantially homogeneous and remain stable and monophasic upon storage. Also provided are methods of using the compositions for pain management and to treat various diseases and conditions, including dementia, sleep disorders, movement disorders, mental disorders, and multiple sclerosis.
Claims21
-145. (canceled)
A pharmaceutical composition comprising about 0.25% w/w to about 2% w/w dronabinol, about 2% w/w to about 10% w/w of a hydrophobic solvent selected from the group consisting of sesame oil, soybean oil, hydrogenated vegetable oil, and combinations thereof, about 30% w/w to about 60% w/w of an alcohol-based solvent, an optional co-solvent, and about 49% w/w to about 61% w/w of a propellant.
A single phase pharmaceutical composition comprising:
- a. about 0.25% w/w to about 2% of w/w dronabinol or a pharmaceutically acceptable salt thereof;
- b. about 2% w/w to about 10% w/w of sesame oil;
- c. about 30% w/w to about 60% w/w of isopropanol;
- d. about 0.5% w/w to about 5% w/w of a co-solvent selected from propylene glycol or benzyl alcohol,
- e. and about 49% w/w to about 61% w/w of 1,1,1,2-tetrafluoroethane.
Dependencies are inferred from the claim text.